Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05698329 · ClinicalTrials.gov registry record · Phase 1
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
A Phase 1 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, sponsored by AiViva BioPharma.
- Active
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 6
- Study locations
NCT05698329 is a Phase 1 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration that is active but no longer recruiting, run by AiViva BioPharma. The registered enrollment target is 19 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT05698329, a Phase 1 study of Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, is active but no longer recruiting, sponsored by AiViva BioPharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 6
- Study locations
Study Summary
To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Conditions Studied
Interventions
- DRUG AIV007
Study Locations (6)
Texas
- Valley Retina Institute - McAllen
- Texas Retina Associates - Plano
- Medical Center Ophthalmology - San Antonio
California
- Retina-Vitreous Associates - Beverly Hills
- Orange County Retina - Santa Ana
Oregon
- Verum Research - Eugene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2023-03-02 |
| Est. Completion | 2025-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05698329
The ClinicalTrials.gov registry entry for NCT05698329 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The listed sponsor is AiViva BioPharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which AIV007 is the first listed.
NCT05698329 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Texas, California, Oregon.
Frequently Asked Questions
What is clinical trial NCT05698329 about?
NCT05698329 is a clinical study titled "Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)". To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
What is the current status of trial NCT05698329?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2023-03-02. Estimated completion is 2025-04-01.
What conditions does trial NCT05698329 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Macular Edema.
What interventions are being tested in trial NCT05698329?
The interventions under investigation include: AIV007 (DRUG).
Who is sponsoring clinical trial NCT05698329?
This trial is sponsored by AiViva BioPharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05698329 being conducted?
This trial has 6 study locations across California, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
Explore more on PlainTrial
Diabetic Macular Edema
All registered trials for this condition
Neovascular Age-related Macular Degeneration
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.